Curated News
By: NewsRamp Editorial Staff
May 30, 2025

Quantum BioPharma (QNTM) Settles Disputes with Former CEO, Injects $2.35M Capital

Reddit Discuss on LinkedIn participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Source News Release

TLDR

  • Quantum BioPharma reaches settlement with former Chairman, injecting $2.35 million USD, resolving disputes and preserving non-dilutive capital.
  • The settlement agreement with Dr. Raza Bokhari brings closure to legal proceedings, bars future litigation, and affirms actions in company's best interest.
  • The settlement injects non-dilutive capital into Quantum BioPharma, fostering growth and innovation for neurodegenerative and metabolic disorder treatments.
  • Quantum BioPharma's settlement with Dr. Raza Bokhari promotes stability, financial growth, and positive impact in the biopharmaceutical industry.

Impact - Why it Matters

This news highlights the resolution of a significant legal dispute for Quantum BioPharma, bringing financial stability and closing the chapter on past conflicts. The settlement allows the company to focus on its innovative drug development efforts, particularly in the treatment of neurodegenerative disorders like multiple sclerosis. The injection of non-dilutive capital and the ongoing royalty payments from Celly Nutrition Corp. position Quantum BioPharma for future growth and success.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has settled all disputes with former Executive Chairman and CEO Dr. Raza Bokhari, with Bokhari agreeing to pay $2.35 million USD to the company. The settlement, signed by Co-Chairmen Zeeshan Saeed and Anthony Durkacz, puts an end to legal battles in the U.S. and Canada, providing non-dilutive capital for the business. Both parties deny wrongdoing and affirm their actions were in the company's best interest.

Quantum BioPharma is focused on developing drug candidates for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, targeting multiple sclerosis. The company also holds a stake in Celly Nutrition Corp. and maintains investments through FSD Strategic Investments Inc. The agreement with Celly Nutrition includes royalty payments to Quantum BioPharma based on sales of UNBUZZD(TM) until reaching $250 million.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Quantum BioPharma (QNTM) Settles Disputes with Former CEO, Injects $2.35M Capital

blockchain registration record for the source press release.